OneSkin is going beneath the surface.
What’s happening: The longevity skincare brand raised $20M from Prelude Growth Partners to support its 2027 retail debut.
Inside-out. Targeting “skinspan,” OneSkin formulates peptide-enriched topicals, from daily serums to scalp care and sunscreen, claiming to boost cellular function, increase collagen production, and reduce inflammation.
Backed by Unilever and sold on Amazon, the brand is projecting $40M–50M in 2025 revenue.
Anti-anti-aging. Because skin health reflects and drives biological aging, the war on wrinkles is being rebranded for the longevity era.
Emphasizing science-backed solutions, Estée Lauder opened the first skin longevity institute, while L’Oréal is leveraging AI and new ingredients to position beauty as a pillar of longevity.
Promising beauty from within, the $8B nutricosmetics industry is betting on clinically validated ingestibles. Launching serums and supps, Martha Stewart’s Elm Biosciences will debut this September.
Punchline: While the language is shifting, beauty x longevity is still selling anti-aging. Long plagued by unfulfilled claims, brands that deliver real results will outlive their competition.
